Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe why rheumatic pain feels different for everyone

NCT ID NCT07829497

NEW Knowledge-focused Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers want to understand the different ways pain works in people with rheumatic diseases such as lupus, rheumatoid arthritis, and Sjogren's syndrome. The study enrolls up to 225 people aged 9 to 85 who have or may have a rheumatic disease, plus healthy volunteers matched by age and sex. Participants answer questionnaires and undergo bedside sensory testing with light touch, vibration, heat, cold, pressure, and sharp sensations to map their pain patterns. The goal is to link these pain profiles to disease activity and quality of life, which could help doctors tailor pain treatment in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bedside quantitative sensory testing
What this could lead to
If researchers can map distinct pain types in rheumatic diseases, doctors may one day match treatments to each person's specific pain mechanism.
What could go wrong
This observational study does not test a treatment, so it will not directly relieve pain. It may not find clear pain patterns, and results from 225 people may not apply to everyone with rheumatic diseases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 225 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2036

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study team will contact participants who are 9 years and older and are enrolled in NIH protocols 01-AR-0227, 94-AR-0066, and 11-AR-0223, because affected participants in this study must have an established or suspected rheumatologic disease and must also be co-enrolled in one of these protocols. Healthy volunteers may include family members of participants enrolled in these studies. Potential participants may also be identified through the Office of Patient Recruitment, direct outreach to local rheumatologists, internists, and university hospital clinics, or referrals from health care providers. However, these individuals must first be enrolled in one of the NIH protocols listed above before joining this study.

Ages

9 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA Inclusion Criteria for Subjects Suspected or Diagnosed with Rheumatic Diseases In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Stated willingness to comply with all study procedures and availability for the duration of the study 2. Aged 9-85 years 3. Diagnosed or suspected of having a rheumatic disease. 4. Ability of the subject to understand and the willingness to sign a written informed consent document or assent. 5. Must be enrolled in one of the NIAMS protocols (01-AR-0227, 94-AR-0066, 11-AR-0223) 6. To be able to answer PRO questionnaires in either English and/or Spanish languages. Inclusion Criteria Healthy Volunteers 1. Stated willingness to comply with all study procedures and availability for the duration of the study 2. Aged 9-85 years 3. No known history of a rheumatic disease or any other chronic medical illness. 4. Ability of the subject to understand and the willingness to sign a written informed consent document or assent. 5. To be enrolled in either of the ongoing NIAMS protocols 01-AR-0227, 94-AR-0066, or 11-AR-0223. 6. To be able to answer PRO questionnaires in either English and/or Spanish languages. EXCLUSION CRITERIA An individual who meets any of the following criteria will be excluded from participation in this study: 1. Treatment with investigational drug or other investigational intervention while enrolled in this study. 2. Any physical exam finding that precludes bedside QST. 3. Developmental delay or cognitive impairment that interfere with following or understanding the test instructions. 4. Subjects using illicit or street drugs will be excluded. Subjects taking prescribed pain medications will not be excluded. 5. Any chronic medical condition that may hinder participation in the study as determined by the study PI.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ankylosing spondylarthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis arthritic joint disease central nervous system lupus rheumatic disorder rheumatoid arthritis Sjogren syndrome Spondylarthritis spondyloarthropathy systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ankylosing spondylarthritis Arthritis Lupus erythematosus, systemic Lupus vasculitis, central nervous system Rheumatic diseases Rheumatoid arthritis Sjogren's syndrome Spondylarthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.